These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26030731)

  • 1. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
    Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R
    Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
    Zheng S; He S; Liang Y; Tan Y; Liu Q; Liu T; Lu X
    Mol Biomed; 2024 Apr; 5(1):13. PubMed ID: 38616230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
    Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
    Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines.
    Xu L; Davidson BJ; Murty VV; Li RG; Sacks PG; Garin-Chesa P; Schantz SP; Chaganti RS
    Int J Cancer; 1994 Nov; 59(3):383-7. PubMed ID: 7927946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
    Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
    Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.